Ligand id: 7932

Name: amuvatinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 107.98
Molecular weight 447.14
XLogP 3.92
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

1. Bearss DJ, Joshi-Hangal R, Liu X-H, Phiasivongsa P, Redkar SG, Vankayalapati H, Az D. (2008)
Cell proliferation; anticancer agents; bioavailability.
Patent number: US20080226747. Assignee: Supergen, Inc.. Priority date: 01/03/2007. Publication date: 18/09/2008.
2. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H et al.. (2007)
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Oncogene, 26 (27): 3909-19. [PMID:17325667]
3. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. (2009)
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells.
Radiat Oncol, 4: 69. [PMID:20028557]
4. Zhao H, Luoto KR, Meng AX, Bristow RG. (2011)
The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination.
Radiother Oncol, 101 (1): 59-65. [PMID:21903282]